Braunstein Scott's Form 4 filing
Marinus Pharmaceuticals, Inc. (MRNS) · filed Feb 11, 2025
- Accession no.
- 0001104659-25-011239
- Filed
- Feb 11, 2025
- Trade date
- Aug 14, 2024-Feb 11, 2025
- Filing delay
- 181 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 9 derivative transactions. Open-market purchases total $6.53K. It was filed 181 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Braunstein ScottCIK 0001643875 | Director, Officer (CHAIRMAN AND CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 14, 2024 | Common Stock | PPurchaseAcquired | +5,933 | $1.10F2 | +$6,526.3 | 304,600 | Direct | |
| Feb 7, 2025 | Common Stock | DReturned to the companyDisposed | −125,064 | $0.55F3 | −$68,785.2 | 179,536 | Direct | |
| Feb 11, 2025 | Common Stock | DReturned to the companyDisposed | −179,536 | $0.55F3 | −$98,744.8 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 11, 2025 | Common Stock | DReturned to the companyDisposed | −167,825 | $0.00 | $0 | 0 | Direct | |
| Feb 11, 2025 | Common Stock | DReturned to the companyDisposed | −335,650 | $0.00 | $0 | 0 | Direct | |
| Feb 11, 2025 | Common Stock | DReturned to the companyDisposed | −360,000 | $0.00 | $0 | 0 | Direct | |
| Feb 11, 2025 | Common Stock | DReturned to the companyDisposed | −193,050 | $0.00 | $0 | 0 | Direct | |
| Feb 11, 2025 | Common Stock | DReturned to the companyDisposed | −290,000 | $0.00 | $0 | 0 | Direct | |
| Feb 11, 2025 | Common Stock | DReturned to the companyDisposed | −450,000 | $0.00 | $0 | 0 | Direct | |
| Feb 11, 2025 | Common Stock | DReturned to the companyDisposed | −200,000 | $0.00 | $0 | 0 | Direct | |
| Feb 11, 2025 | Common Stock | DReturned to the companyDisposed | −15,917 | $0.00 | $0 | 0 | Direct | |
| Feb 11, 2025 | Common Stock | DReturned to the companyDisposed | −7,500 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.09 to $1.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of Common Stock held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash.
Referenced by the price of 2 transactions in Table I.